{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:41Z","timestamp":1791612641510,"version":"4.3.4"},"reference-count":155,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of patients develop end-stage renal disease. The discovery of autoantibodies such as phospholipase A2 receptor 1, antithrombospondin and neural epidermal growth factor-like 1 protein has greatly helped us to understand the pathogenesis and enable the diagnosis of this disease and to guide its treatment. Depending on the complications of nephrotic syndrome, patients with this disease receive supportive treatment with diuretics, ACE inhibitors or angiotensin-receptor blockers, lipid-lowering agents and anticoagulants. After assessing the risk of progression of end-stage renal disease, patients receive immunosuppressive therapy with various drugs such as cyclophosphamide, steroids, calcineurin inhibitors or rituximab. Since immunosuppressive drugs can cause life-threatening side effects and up to 30% of patients do not respond to therapy, new therapeutic approaches with drugs such as adrenocorticotropic hormone, belimumab, anti-plasma cell antibodies or complement-guided drugs are currently being tested. However, special attention needs to be paid to the choice of therapy in secondary forms or in specific clinical contexts such as membranous disease in children, pregnant women and patients undergoing kidney transplantation.<\/jats:p>","DOI":"10.3390\/medicina59111997","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:03:45Z","timestamp":1699959825000},"page":"1997","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["How to Choose the Right Treatment for Membranous Nephropathy"],"prefix":"10.3390","volume":"59","author":[{"given":"Luigi","family":"Peritore","sequence":"first","affiliation":[{"name":"Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Labbozzetta","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Maressa","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6348-8718","authenticated-orcid":false,"given":"Chiara","family":"Casuscelli","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-500X","authenticated-orcid":false,"given":"Giovanni","family":"Conti","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, AOU Policlinic \u201cG Martino\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4823-9910","authenticated-orcid":false,"given":"Guido","family":"Gembillo","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-6559","authenticated-orcid":false,"given":"Domenico","family":"Santoro","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ronco, P., Plaisier, E., and Debiec, H. (2021). Advances in Membranous Nephropathy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040607"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, Y., Yu, X., Zhang, W., Lv, J., Lan, P., Wang, Z., Sun, J., Xie, L., Lu, W., and Feng, X. (2022). Epidemiological characteristics and pathological changes of primary glomerular diseases. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272237"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000500142","article-title":"A Global Evolutionary Trend of the Frequency of Primary Glomerulonephritis over the Past Four Decades","volume":"5","author":"Woo","year":"2019","journal-title":"Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"Hladunewich","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3389\/fimmu.2018.03035","article-title":"Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated Membranous Nephropathy","volume":"9","author":"Reinhard","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/1744666X.2019.1548934","article-title":"Characterization of autoantibodies in primary membranous nephropathy and their clinical significance","volume":"15","author":"Stahl","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.xkme.2021.03.013","article-title":"Primary Membranous Nephropathy with Enhanced Staining of Exostosin 1\/Exostosin 2 in the Glomeruli: A Report of 2 Cases","volume":"3","author":"Iwakura","year":"2021","journal-title":"Kidney Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2021.08.025","article-title":"Contactin 1, a Potential New Antigen Target in Membranous Nephropathy: A Case Report","volume":"80","author":"Santoro","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.34067\/KID.0001492021","article-title":"Transforming Growth Factor Beta Receptor 3 (TGFBR3)\u2013Associated Membranous Nephropathy","volume":"2","author":"Caza","year":"2021","journal-title":"Kidney360"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-Associated Membranous Nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Caza","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.2022050608","article-title":"Netrin G1 is a Novel Target Antigen in Primary Membranous Nephropathy","volume":"33","author":"Reinhard","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pozdzik, A., Broch\u00e9riou, I., David, C., Touzani, F., Goujon, J.M., and Wissing, K.M. (2018). Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/6281054"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2022.12.003","article-title":"Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy","volume":"8","author":"Vink","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ekir.2023.01.024","article-title":"\u2018Precision\u2019 Medicine in Membranous Nephropathy: Serology-Guided Therapy","volume":"8","author":"Glassock","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfac237","article-title":"The Many Faces of NELL1 MN","volume":"16","author":"Sethi","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: What we know and what remains a decade after its discovery","volume":"96","author":"Fresquet","year":"2019","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","article-title":"Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome","volume":"32","author":"Wiech","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_28","first-page":"479","article-title":"Diagnosis and management of nephrotic syndrome in adults","volume":"93","author":"Kodner","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure","volume":"56","author":"Jentzer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/cells4040622","article-title":"Albumin and furosemide combination for management of edema in nephrotic syndrome: A review of clinical studies","volume":"4","author":"Duffy","year":"2015","journal-title":"Cells"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MNH.0000000000000290","article-title":"Mineralocorticoid antagonists in chronic kidney disease","volume":"26","author":"Bakris","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028019843644","article-title":"Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature","volume":"53","author":"Steuber","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial","volume":"3","author":"Cressman","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_35","first-page":"CD005425","article-title":"Lipid-lowering agents for nephrotic syndrome","volume":"2013","author":"Kong","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.kint.2016.01.019","article-title":"Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?","volume":"89","author":"Hofstra","year":"2016","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Collaborative Study of the Adult Idiopathic Nephrotic Syndrome (1979). A Controlled Study of Short-Term Prednisone Treatment in Adults with Membranous Nephropathy. N. Engl. J. Med., 301, 1301\u20131306.","DOI":"10.1056\/NEJM197912133012401"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/oxfordjournals.qjmed.a068422","article-title":"The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party","volume":"74","author":"Cameron","year":"1990","journal-title":"Q. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ki.1974.129","article-title":"Controlled trial of cyclophosphamide in idiopathic membranous nephropathy","volume":"6","author":"Donadio","year":"1974","journal-title":"Kidney Int."},{"key":"ref_41","first-page":"655","article-title":"Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a \u2018controlled\u2019 study","volume":"81","author":"Lagrue","year":"1975","journal-title":"J. Urol. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group","volume":"327","author":"Ponticelli","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0272-6386(12)70259-7","article-title":"Short-term responsiveness of membranous glomerulopathy to cyclosporine","volume":"20","author":"Guasch","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000187219","article-title":"Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy","volume":"63","author":"Rostoker","year":"1993","journal-title":"Nephron"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000167436","article-title":"Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin","volume":"7","author":"DeSanto","year":"1987","journal-title":"Am. J. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Shang, S.-L., Cai, G.-Y., Duan, S.-W., Li, P., Li, Q.-G., and Chen, X.-M. (2018). Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0967-5"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ndt\/gfu306","article-title":"Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus","volume":"30","author":"Caro","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: A multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am. J. Med. Sci."},{"key":"ref_53","first-page":"979","article-title":"Efficacy and safety of long-course tacrolimus treatment for idiopathic membranous nephropathy","volume":"16","author":"Di","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide","volume":"50","author":"Branten","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study","volume":"23","author":"Nayagam","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Justino","year":"2021","journal-title":"Kidney Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy","volume":"14","author":"Dahan","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_63","first-page":"1691","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Emery","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"Emery","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy","volume":"28","author":"Ruggenenti","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ckj\/sfad041","article-title":"Future landscape for the management of membranous nephropathy","volume":"16","author":"Yandian","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel Treatments Paradigms: Membranous Nephropathy","volume":"8","author":"Ortiz","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/ndt\/gfh110","article-title":"ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses","volume":"19","author":"Berg","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"van de Logt, A.-E., Beerenhout, C.H., Brink, H.S., van de Kerkhof, J.J., Wetzels, J.F., and Hofstra, J.M. (2015). Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142033"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.kint.2019.04.018","article-title":"ACTH (corticotrophin) therapy in resistant primary membranous nephropathy","volume":"96","author":"Bagchi","year":"2019","journal-title":"Kidney Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Barrett","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono","year":"2014","journal-title":"J. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000515087","article-title":"Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy","volume":"1","author":"Geara","year":"2021","journal-title":"Glomerular Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1009864","DOI":"10.3389\/fimmu.2022.1009864","article-title":"The role of the complement system in primary membranous nephropathy: A narrative review in the era of new therapeutic targets","volume":"13","author":"So","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2019.05.021","article-title":"Treatment of Membranous Nephropathy in Patients with THSD7A Antibodies Using Immunoadsorption","volume":"74","author":"Holtz","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000501858","article-title":"Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab","volume":"144","author":"Gennarini","year":"2020","journal-title":"Nephron"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Arghiani, M., Zamani, B.H., Nazemian, F., Samadi, S., Afsharian, M.S., Habibzadeh, M., Eslami, S., and Sabbagh, M.G. (2021). A cohort study of membranous nephropathy, primary or secondary. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02338-6"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous Nephropathy: Core Curriculum 2021","volume":"77","author":"Alsharhan","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ndt\/gfg616","article-title":"Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy","volume":"19","author":"Ohtani","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_84","first-page":"591","article-title":"The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiation Primary Membranous Nephropathy from Secondary Membranous Nephropathy in Renal Biopsy","volume":"26","author":"Yeo","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"611317","DOI":"10.3389\/fmed.2020.611317","article-title":"Moroni, G.; Ponticelli, C. Secondary Membranous Nephropathy. A Narrative Review","volume":"7","author":"Beck","year":"2020","journal-title":"Front. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s13730-021-00641-7","article-title":"Membranous nephropathy in a patient with pulmonary tuberculosis infection and lung adenocarcinoma: A case report","volume":"11","author":"Morimoto","year":"2022","journal-title":"CEN Case Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13730-014-0135-0","article-title":"A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma","volume":"4","author":"Kaneko","year":"2015","journal-title":"CEN Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"898811","DOI":"10.3389\/fimmu.2022.898811","article-title":"Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma","volume":"13","author":"Ratanasrimetha","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4103\/ijn.ijn_415_21","article-title":"Nell1 as Target Antigen for Mercury Related Membranous Nephropathy: A Case Report","volume":"32","author":"Pathak","year":"2022","journal-title":"Indian J. Nephrol."},{"key":"ref_90","first-page":"31","article-title":"Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis","volume":"3","author":"Sewaralthahab","year":"2014","journal-title":"Clin. Nephrol.\u2014Case Stud."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e1243","DOI":"10.1097\/MD.0000000000001243","article-title":"Membranous Nephropathy Associated with Immunological Disorder-Related Liver Disease","volume":"94","author":"Dauvergne","year":"2015","journal-title":"Medicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s13730-019-00399-z","article-title":"Membranous nephropathy caused by rheumatoid arthritis","volume":"8","author":"Iida","year":"2019","journal-title":"CEN Case Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e8201","DOI":"10.1097\/MD.0000000000008201","article-title":"Membranous nephropathy in a patient with ankylosing spondylitis","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s13730-021-00672-0","article-title":"A case of membranous nephropathy secondary to asymptomatic Graves\u2019 disease","volume":"11","author":"Moniwa","year":"2022","journal-title":"CEN Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"824124","DOI":"10.3389\/fimmu.2022.824124","article-title":"Membranous Nephropathy Secondary to Graves\u2019 Disease: A Case Report","volume":"13","author":"Neves","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00467-008-0973-0","article-title":"Membranous nephropathy associated with thyroid-peroxidase antigen","volume":"24","author":"Shima","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2050313X19869764","DOI":"10.1177\/2050313X19869764","article-title":"Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy","volume":"7","author":"Hanna","year":"2019","journal-title":"SAGE Open Med Case Rep."},{"key":"ref_98","first-page":"13","article-title":"Celiac Disease as a Rare Cause of Membranous Nephropathy: A Case Report Case Presentation","volume":"13","author":"Pestana","year":"2021","journal-title":"Cureus"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"543","DOI":"10.12659\/AJCR.889684","article-title":"Membranous glomerulonephritis associated with Mycobacterium shimoidei pulmonary infection","volume":"14","author":"Matsunaga","year":"2013","journal-title":"Am. J. Case Rep."},{"key":"ref_100","first-page":"119","article-title":"Hepatitis B viremia manifesting as polyarteritis nodosa and secondary membranous nephropathy","volume":"5","author":"Balwani","year":"2016","journal-title":"J. Nephropharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2324709620967212","DOI":"10.1177\/2324709620967212","article-title":"Membranous Glomerulonephritis as an Uncommon Presentation of Secondary Syphilis: A Reminder on Therapeutic Decision-Making in Clinical Practice","volume":"8","author":"Inayat","year":"2020","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"17-062","DOI":"10.7812\/TPP\/17-062","article-title":"Secondary Syphilis Associated with Membranous Nephropathy and Acute Hepatitis in a Patient with HIV: A Case Report","volume":"22","author":"Zhang","year":"2018","journal-title":"Perm. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2169\/internalmedicine.9655-22","article-title":"Chronic Graft-versus-host Disease-associated Membranous Nephropathy Following Bone Marrow Transplantation, Successfully Treated with Rituximab","volume":"62","author":"Sakai","year":"2023","journal-title":"Intern. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Gembillo, G., Siligato, R., Cernaro, V., and Santoro, D. (2020). Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist\u2019s Opinion. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051261"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Saiki, R., Katayama, K., Hirabayashi, Y., Oda, K., Fujimoto, M., Murata, T., Nakajima, A., and Dohi, K. (2021). Membranous nephropathy associated with multicentric Castleman\u2019s disease that was successfully treated with tocilizumab: A case report and review of the literature. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02423-w"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12882-020-02191-z","article-title":"Idiopathic multicentric Castleman disease with Sj\u00f6gren\u2019s syndrome and secondary membranous nephropathy: A case report and review of the literature","volume":"21","author":"Pan","year":"2020","journal-title":"BMC Nephrol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1108994","DOI":"10.3389\/fonc.2023.1108994","article-title":"Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis","volume":"13","author":"Lovato","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/1756-185X.13321","article-title":"Induction therapy for membranous lupus nephritis: A systematic review and network meta-analysis","volume":"1","author":"Tang","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_109","first-page":"390","article-title":"Membranous Nephropathy Associated with Sarcoidosis: A Primary or Secondary Glomerulopathy?","volume":"16","author":"Zilberman","year":"2014","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the nephrotic syndrome study network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2215\/CJN.11461017","article-title":"The Spectrum of Biopsy-Proven Glomerular Diseases among Children in China","volume":"13","author":"Nie","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/ndt\/gfr221","article-title":"Pathology of idiopathic nephrotic syndrome in children: Are the adolescents different from young children?","volume":"27","author":"Mubarak","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2215\/CJN.06220518","article-title":"Evolving Epidemiology of Pediatric Glomerular Disease","volume":"13","author":"Rheault","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.prp.2019.01.046","article-title":"Pathology-Research and Practice Compared staining of the phospholipase A2 receptor in the glomeruli of Chinese adults and children with idiopathic membranous nephropathy","volume":"215","author":"Zhang","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40620-020-00816-y","article-title":"Long-term renal survival and related risk factors for primary membranous nephropathy in Chinese children: A retrospective analysis of 217 cases","volume":"34","author":"Wang","year":"2020","journal-title":"J. Nephrol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00467-020-04798-8","article-title":"Primary membranous nephropathy in children and adolescents: A single-centre report from South Asia","volume":"36","author":"Ramachandran","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00467-017-3817-y","article-title":"Immunohistochemical and serological characterization of membranous nephropathy in children and adolescents","volume":"33","author":"Dettmar","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1007\/s00467-022-05503-7","article-title":"Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population","volume":"37","author":"Miller","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00467-018-3923-5","article-title":"Idiopathic membranous nephropathy in children treated with rituximab: Report of two cases Case description","volume":"33","author":"Eldin","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00467-008-1005-9","article-title":"Membranous glomerulonephritis: Treatment response and outcome in children","volume":"24","author":"Valentini","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00467-006-0246-8","article-title":"Idiopathic membranous nephropathy in pediatric patients: Presentation, response to therapy, and long-term outcome","volume":"21","author":"Lee","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chen, A., Frank, R., Vento, S., Crosby, V., Chandra, M., Gauthier, B., Valderrama, E., and Trachtman, H. (2007). Idiopathic membranous nephropathy in pediatric patients: Presentation, response to therapy, and long-term outcome. BMC Nephrol., 8.","DOI":"10.1186\/1471-2369-8-11"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5414\/CN107642","article-title":"Mycophenolate mofetil therapy in children with idiopathic membranous nephropathy","volume":"80","author":"Bhimma","year":"2013","journal-title":"Clin. Nephrol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"884","DOI":"10.24953\/turkjped.2020.05.025","article-title":"Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome","volume":"62","author":"Bayram","year":"2020","journal-title":"Turk. J. Pediatr."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"962502","DOI":"10.3389\/fimmu.2022.962502","article-title":"Pediatric membranous nephropathy: In the novel antigens era","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Yamaguchi, T., Tsuji, S., Akagawa, S., Akagawa, Y., Kino, J., Yamanouchi, S., Kimata, T., Hashiyada, M., Akane, A., and Kaneko, K. (2021). Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome. Nutrients, 13.","DOI":"10.3390\/nu13020365"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1753495X18816923","article-title":"Case study of tacrolimus as an effective treatment for idiopathic membranous glomerulonephritis in pregnancy","volume":"13","author":"Irish","year":"2020","journal-title":"Obstet. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2018.06.006","article-title":"Renal Disorders in Pregnancy: Core Curriculum 2019","volume":"73","author":"Suarez","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000151336","article-title":"Successful management of pregnancy with nephrotic syndrome due to preexisting membranous glomerulonephritis: A case report","volume":"24","author":"Sebestyen","year":"2008","journal-title":"Fetal Diagn. Ther."},{"key":"ref_130","first-page":"56","article-title":"Membranous glomerulonephritis and pregnancy","volume":"28","author":"Packham","year":"1987","journal-title":"Clin. Nephrol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000505175","article-title":"Membranous Nephropathy in Pregnancy","volume":"51","author":"Liu","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"337.e1\u201314","DOI":"10.1016\/j.ajog.2014.09.031","article-title":"Chronic hypertension in pregnancy and the risk of congenital malformations: A cohort study","volume":"212","author":"Bateman","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"563094","DOI":"10.3389\/fmed.2020.563094","article-title":"Maternal and Fetal Outcomes of Pregnancy in Nephrotic Syndrome Due to Primary Glomerulonephritis","volume":"7","author":"Siligato","year":"2020","journal-title":"Front. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Infante, B., Rossini, M., Leo, S., Troise, D., Netti, G.S., Ranieri, E., Gesualdo, L., Castellano, G., and Stallone, G. (2020). Recurrent glomerulonephritis after renal transplantation: The clinical problem. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21175954"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1097\/TP.0000000000002758","article-title":"Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management","volume":"103","author":"Leon","year":"2019","journal-title":"Transplantation"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1432-2277.2012.01548.x","article-title":"De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease?","volume":"25","author":"Ponticelli","year":"2012","journal-title":"Transpl. Int."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2169\/internalmedicine.55.5468","article-title":"Post-Transplant Membranous Nephropathy Associated with Chronic Active Antibody-Mediated Rejection and Hepatitis C Infection after Deceased Donor Renal Transplantation","volume":"55","author":"TDoke","year":"2016","journal-title":"Intern. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0041-1345(01)02803-2","article-title":"An early case of de novo membranous nephropathy in a renal transplant patient","volume":"34","author":"Pinto","year":"2002","journal-title":"Transplant. Proc."},{"key":"ref_140","first-page":"8","article-title":"A Case of De Novo Membranous Nephropathy Causing Renal Transplant Rejection","volume":"11","author":"Kurkowski","year":"2022","journal-title":"Cureus"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1600-6143.2008.02237.x","article-title":"Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study","volume":"8","author":"Dabade","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/ajt.13133","article-title":"Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy","volume":"15","author":"Kattah","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.kint.2020.08.007","article-title":"HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients","volume":"99","author":"Berchtold","year":"2021","journal-title":"Kidney Int."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.transproceed.2011.10.042","article-title":"Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts","volume":"43","author":"Kearney","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.ajkd.2020.01.009","article-title":"Association of HLA Typing and Alloimmunity with Posttransplantation Membranous Nephropathy: A Multicenter Case Series","volume":"76","author":"Batal","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent Membranous Nephropathy After Kidney Transplantation: Treatment and Long-Term Implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.00280121","article-title":"Recurrent glomerular disease after kidney transplantation diagnostic and management dilemmas","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1111\/j.1600-6143.2009.02851.x","article-title":"Recurrent idiopathic membranous nephropathy: Early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies","volume":"9","author":"Grande","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5500\/wjt.v12.i1.15","article-title":"Is de novo membranous nephropathy suggestive of alloimmunity in renal transplantation? A case report","volume":"12","author":"Darji","year":"2022","journal-title":"World J. Transplant."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1111\/ajt.16610","article-title":"Posttransplant nephrotic syndrome resulting from NELL1-positive membranous nephropathy","volume":"21","author":"Weimann","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1681\/ASN.2021101323","article-title":"Recurrence of Anti-semaphorin-3B Mediated Membranous Nephropathy after Kidney Transplantation","volume":"33","author":"Fila","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Xu, W., Zhang, Z., Li, D., Dai, W., Pan, C., Guo, M., Zhao, Y., and Cui, X. (2023). Immunosuppressive therapy for progressive idiopathic membranous nephropathy: A cost-effectiveness analysis in China. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-09365-z"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/ndt\/gfy049","article-title":"Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: A health economic model","volume":"33","author":"Hamilton","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"107376","DOI":"10.1016\/j.intimp.2021.107376","article-title":"Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis","volume":"94","author":"Dai","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","article-title":"Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli\u2019s regimen in membranous nephropathy","volume":"34","author":"Fenoglio","year":"2021","journal-title":"J. Nephrol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/11\/1997\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:22:41Z","timestamp":1760131361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/11\/1997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":155,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["medicina59111997"],"URL":"https:\/\/doi.org\/10.3390\/medicina59111997","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}